Apimeds Pharmaceuticals US, Inc
APUSAMEXHealthcareBiotechnology
Previous close
$4.84
+$0.45 · +10.25%
APUS company overview
Historical prices · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
19
Strong Down
Sentiment
51
Mixed
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteApimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Vinod Menon
- Listed since
- May 9, 2025
- Employees
- 7
Market position
Day range
Current $4.84
52-week range
Current $4.84
- Open
- $4.30
- Previous close
- $4.39
- Volume
- 555.48K
- 8.91× average
- Average volume
- 62.34K
- Average daily volume
- Market cap
- 7.3M USD
- Beta
- 0.15
- Market reference 1
- 50-day average
- $7.1614
- -32.42% below average
- 200-day average
- $15.3275
- -68.42% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 23.97M USD
- EV / EBITDA
- -4.2×
- Earnings yield
- -33.63%
- Free cash flow yield
- -50.34%
Profitability & efficiency
- Return on equity
- -3.91%
- Return on assets
- -3.66%
- Return on invested capital
- -7.39%
Financial health
- Current ratio
- 1.31×
- Altman Z-score
- -2
- Piotroski F-score
- 1 of 9
Earnings
- Latest fiscal-year EPS
- -5.5
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
APUS peers
ETFs holding APUS
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research APUSresearch.disclaimer